Abstract
BackgroundBehçet’s disease (BD), a chronic systemic vasculitis, has distinct geographical and ethnic variation. Data regarding the epidemiology of patients with BD in the U.S. are limited; therefore, we sought to describe BD patient characteristics and medication use in the U.S., and compared them with data from patients from endemic regions.MethodsWe conducted a cross-sectional study using data from the RISE registry (2014–2018). Patients aged ≥ 18 years with BD were included. Sociodemographic and treatment information was extracted. We compared patients from the RISE registry to data from other published studies of patients with BD from endemic areas.ResultsOne thousand three hundred twenty-three subjects with BD from the RISE registry were included. Mean age was 48.7 ± 16.3 years, female to male ratio was 3.8:1, and 66.7% were White. The most frequently used medications included glucocorticoids (67.6%) and colchicine (55.0%). Infliximab and adalimumab were the most used biologics (14.5% and 14.1%, respectively); 3.2% of patients used apremilast. The RISE registry had more women (79.3%), and patients were older compared to previously published BD studies from endemic areas. Methotrexate and TNFi were more commonly reported in RISE (21.8% and 29.4%) compared to studies from Egypt and Turkey. Colchicine, cyclosporine, and cyclophosphamide were more commonly used in cohorts from Egypt, Turkey, and Iran.ConclusionsFindings from the largest BD dataset in the U.S. suggest that BD patients are predominantly female. Further research is needed to explore the reasons for the higher prevalence of BD among women in the U.S. and its possible impact on disease severity and management.
Highlights
Behçet’s disease (BD), a chronic systemic vasculitis, has distinct geographical and ethnic variation
Findings from the largest BD dataset in the U.S suggest that BD patients are predominantly female
Further research is needed to explore the reasons for the higher prevalence of BD among women in the U.S and its possible impact on disease severity and management
Summary
Behçet’s disease (BD), a chronic systemic vasculitis, has distinct geographical and ethnic variation. Data regarding the epidemiology of patients with BD in the U.S are limited; we sought to describe BD patient characteristics and medication use in the U.S, and compared them with data from patients from endemic regions. While descriptive cohort studies of BD in the U.S exist, they are from single centers, limited by small sample sizes, and have not reported data from multiple racial or ethnic groups [2, 4,5,6]. Previous studies comparing the characteristics of patients with BD from the northeastern U.S with patients from Turkey [5] and Iran [7] raised the possibility that BD in U.S patients may have unique features compared to typical BD populations. To date, no national studies of BD in the U.S have been published
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
